Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)

Danni Li, Jeffrey R. Misialek, Eric Boerwinkle, Rebecca F. Gottesman, A. Richey Sharrett, Thomas H. Mosley, Josef Coresh, Lisa M. Wruck, David S Knopman, Alvaro Alonso

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Introduction: Phospholipids are altered in brains of patients with dementia and some studies suggest their plasma levels may be useful in the detection of mild cognitive impairment (MCI) and dementia. Methods: We measured 188 plasma metabolites in participants who underwent a detailed neuropsychological assessment and classified as normal (n = 153), MCI (n = 145), or dementia (n = 143) by expert adjudication. Results: Among 10 phospholipids recently implicated as altered in dementia, higher concentration of PC aa C36:6 was significantly associated with decreased prevalence of dementia (odds ratio = 0.71, 95% confidence interval = 0.50-1.00 per 1-SD increase). Adding these phospholipids to a model including multiple predictors of dementia led to only minimal improvement in detection (C statistic changed from 0.702 to 0.71). Discussion: Some phospholipids and metabolites were altered in MCI and dementia but cross-sectional association was relatively weak and did not improve detection of MCI and dementia beyond information provided by clinical variables.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume3
DOIs
StatePublished - 2016

Fingerprint

Dementia
Phospholipids
Cognitive Dysfunction
Odds Ratio
Confidence Intervals
Brain

Keywords

  • AD
  • Alzheimer's disease
  • ARIC
  • ARIC-NCS
  • Dementia
  • MCI
  • Metabolites
  • Metabolomics
  • Mild cognitive impairment
  • Phospholipids
  • Plasma

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS). / Li, Danni; Misialek, Jeffrey R.; Boerwinkle, Eric; Gottesman, Rebecca F.; Sharrett, A. Richey; Mosley, Thomas H.; Coresh, Josef; Wruck, Lisa M.; Knopman, David S; Alonso, Alvaro.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 3, 2016, p. 73-82.

Research output: Contribution to journalArticle

Li, Danni ; Misialek, Jeffrey R. ; Boerwinkle, Eric ; Gottesman, Rebecca F. ; Sharrett, A. Richey ; Mosley, Thomas H. ; Coresh, Josef ; Wruck, Lisa M. ; Knopman, David S ; Alonso, Alvaro. / Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS). In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2016 ; Vol. 3. pp. 73-82.
@article{5ff9658829484cadb95a5b7a3b14c041,
title = "Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)",
abstract = "Introduction: Phospholipids are altered in brains of patients with dementia and some studies suggest their plasma levels may be useful in the detection of mild cognitive impairment (MCI) and dementia. Methods: We measured 188 plasma metabolites in participants who underwent a detailed neuropsychological assessment and classified as normal (n = 153), MCI (n = 145), or dementia (n = 143) by expert adjudication. Results: Among 10 phospholipids recently implicated as altered in dementia, higher concentration of PC aa C36:6 was significantly associated with decreased prevalence of dementia (odds ratio = 0.71, 95{\%} confidence interval = 0.50-1.00 per 1-SD increase). Adding these phospholipids to a model including multiple predictors of dementia led to only minimal improvement in detection (C statistic changed from 0.702 to 0.71). Discussion: Some phospholipids and metabolites were altered in MCI and dementia but cross-sectional association was relatively weak and did not improve detection of MCI and dementia beyond information provided by clinical variables.",
keywords = "AD, Alzheimer's disease, ARIC, ARIC-NCS, Dementia, MCI, Metabolites, Metabolomics, Mild cognitive impairment, Phospholipids, Plasma",
author = "Danni Li and Misialek, {Jeffrey R.} and Eric Boerwinkle and Gottesman, {Rebecca F.} and Sharrett, {A. Richey} and Mosley, {Thomas H.} and Josef Coresh and Wruck, {Lisa M.} and Knopman, {David S} and Alvaro Alonso",
year = "2016",
doi = "10.1016/j.dadm.2016.02.008",
language = "English (US)",
volume = "3",
pages = "73--82",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)

AU - Li, Danni

AU - Misialek, Jeffrey R.

AU - Boerwinkle, Eric

AU - Gottesman, Rebecca F.

AU - Sharrett, A. Richey

AU - Mosley, Thomas H.

AU - Coresh, Josef

AU - Wruck, Lisa M.

AU - Knopman, David S

AU - Alonso, Alvaro

PY - 2016

Y1 - 2016

N2 - Introduction: Phospholipids are altered in brains of patients with dementia and some studies suggest their plasma levels may be useful in the detection of mild cognitive impairment (MCI) and dementia. Methods: We measured 188 plasma metabolites in participants who underwent a detailed neuropsychological assessment and classified as normal (n = 153), MCI (n = 145), or dementia (n = 143) by expert adjudication. Results: Among 10 phospholipids recently implicated as altered in dementia, higher concentration of PC aa C36:6 was significantly associated with decreased prevalence of dementia (odds ratio = 0.71, 95% confidence interval = 0.50-1.00 per 1-SD increase). Adding these phospholipids to a model including multiple predictors of dementia led to only minimal improvement in detection (C statistic changed from 0.702 to 0.71). Discussion: Some phospholipids and metabolites were altered in MCI and dementia but cross-sectional association was relatively weak and did not improve detection of MCI and dementia beyond information provided by clinical variables.

AB - Introduction: Phospholipids are altered in brains of patients with dementia and some studies suggest their plasma levels may be useful in the detection of mild cognitive impairment (MCI) and dementia. Methods: We measured 188 plasma metabolites in participants who underwent a detailed neuropsychological assessment and classified as normal (n = 153), MCI (n = 145), or dementia (n = 143) by expert adjudication. Results: Among 10 phospholipids recently implicated as altered in dementia, higher concentration of PC aa C36:6 was significantly associated with decreased prevalence of dementia (odds ratio = 0.71, 95% confidence interval = 0.50-1.00 per 1-SD increase). Adding these phospholipids to a model including multiple predictors of dementia led to only minimal improvement in detection (C statistic changed from 0.702 to 0.71). Discussion: Some phospholipids and metabolites were altered in MCI and dementia but cross-sectional association was relatively weak and did not improve detection of MCI and dementia beyond information provided by clinical variables.

KW - AD

KW - Alzheimer's disease

KW - ARIC

KW - ARIC-NCS

KW - Dementia

KW - MCI

KW - Metabolites

KW - Metabolomics

KW - Mild cognitive impairment

KW - Phospholipids

KW - Plasma

UR - http://www.scopus.com/inward/record.url?scp=84975517266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975517266&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2016.02.008

DO - 10.1016/j.dadm.2016.02.008

M3 - Article

AN - SCOPUS:84975517266

VL - 3

SP - 73

EP - 82

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -